Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

January 19, 2024

Study Completion Date

May 23, 2024

Conditions
Solid TumorExtensive-stage Small Cell Lung Cancer
Interventions
DRUG

BNT411

intravenous

DRUG

Atezolizumab

intravenous

DRUG

Carboplatin

intravenous

DRUG

Etoposide

intravenous

Trial Locations (12)

20246

University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg

28022

Clinica Universidad de Navarra, Madrid

28050

START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC), Madrid

29605

Prisma Health-Upstate Cancer Institute, Greenville

46026

Hospital Universitario La Fe de Valencia, Valencia

50937

Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Cologne

55131

Universitaetsmedizin der Johannes Gutenberg Universitat Mainz KoeR - (Recruiting only for part 1B and part 2), Mainz

60611

Northwestern Medical Faculty Foundation, Chicago

90048

Cedars-Sinai Medical Center, Los Angeles

08035

Hospital Universitari Vall d'Hebron, Barcelona

EH4 2XU

Edinburgh Cancer Research Centre, Edinburgh

W1G 6AD

Sarah Cannon Research Institute, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioNTech SE

INDUSTRY

NCT04101357 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Biotech Hunter | Biotech Hunter